(Reuters) -Telehealth firm LifeMD said on Tuesday it would offer Danish drugmaker Novo Nordisk's diabetes drug Ozempic at $499 per month to eligible U.S. patients. Eligible self-pay and uninsured ...

LifeMD’s telehealth platform is seamlessly integrated with NovoCare ® Pharmacy to provide easy, reliable access to Novo Nordisk’s FDA-approved GLP-1 medications, Ozempic ® and Wegovy ®, at the most ...

GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible ...

Most people associate medical ultrasounds with baby bumps, but that's just one of many reasons to consider getting an ultrasound.

In this interview, Patel recommends that providers adapt by updating financial assistance policies, expanding patient financing options, and emphasizing price transparency to better inform patients of ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 diabetes patients in the U.S. The company said in March that it was cutting the ...

Casper (Wyo.) Orthopedics began offering bundled self-pay options, according to an Aug. 12 news release shared with Becker’s. The self-pay program offers transparent pricing for services including ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients without insurance. The company launched 7.5 mg and 10 mg vials of ...